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We recently reported that some clinically approved antifungal drugs are potent inhibitors of 
human cytomegalovirus (HCMV). Here, we report the broad-spectrum activity against 
HCMV of isavuconazole (ICZ), a new extended-spectrum triazolic antifungal drug. ICZ 
inhibited the replication of clinical isolates of HCMV as well as strains resistant to the 
currently available DNA polymerase inhibitors. The antiviral activity of ICZ against HCMV 
could be linked to the inhibition of human cytochrome P450 51 (hCYP51), an enzyme whose 
activity we previously demonstrated to be required for productive HCMV infection. 
Moreover, time-of-addition studies indicated that ICZ might have additional inhibitory 
effects during the first phase of HCMV replication. Importantly, ICZ showed synergistic 
antiviral activity in vitro when administered in combination with different approved anti-
HCMV drugs at clinically relevant doses. Together, these results pave the way to possible 
future clinical studies aimed at evaluating the repu posing potential of ICZ in the treatment 
of HCMV-associated diseases.  
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 Human cytomegalovirus (HCMV) is a β-herpesvirus which is a major cause of 
morbidity and mortality in immunocompromised population, particularly transplant 
recipients, immunosuppressed subjects, and AIDS patients (Griffiths et al., 2015). Moreover, 
HCMV is the viral leading cause of congenital defects in newborns (live at birth) when the 
infection is acquired during pregnancy (Rawlinson et al., 2017). Congenital HCMV is indeed 
associated with neurodevelopmental defects including hearing loss and mental deficits; very 
recently, also microcephaly has been linked to congenital HCMV infection (Messinger et al., 
2020).  
Currently, anti-HCMV therapy relies only on a few drugs and a vaccine is lacking 
(Britt & Prichard, 2018). All drugs have viral targets, i.e., the viral DNA polymerase 
(targeted by ganciclovir and its prodrug valganciclovir, acyclovir and its prodrug 
valacyclovir, foscarnet, and cidofovir) and the viral terminase complex (targeted by 
letermovir, the latest in order of license) (Britt & Prichard, 2018). The use of DNA 
polymerase inhibitors is however limited in some relevant clinical settings, including 
infections with drug-resistant or refractory HCMV strains, and congenital and pediatric 
infections (Meesing & Razonable, 2018). Moreover, the use of letermovir is restricted to 
adult HCMV-seropositive stem cell transplant recipients and has been associated to 
emergence of drug-resistant strains (Gerna et al., 2019; Douglas et al., 2018). Thus, there is 
still an urgent need for the development of alternative anti-HCMV therapeutic strategies.  
 Targeting host pathways relevant for virus replication and pathogenesis represents a 
promising approach that could overcome some issues ch as viral resistance. Moreover, 










antiviral agents targeting the virus, exploiting the different mechanisms of action and the 
expected synergistic effect (Cai et al., 2014; Oiknine-Djian et al., 2019). Also repurposing 
existing drugs as antiviral agents and exploit them alone or in combination is a promising 
and convenient antiviral strategy for the development of new therapeutic protocols 
(Mercorelli et al., 2018a). The current Severe Acute Respiratory Syndrome Coronavirus-2 
(SARS-COV-2) pandemic offers an example of how thisapproach could be beneficial in the 
treatment of viral infections (Valle et al., 2020; Saul & Einav, 2020).  
Here, we describe for the first time the anti-HCMV activity of isavuconazole, a new, 
extended-spectrum, clinically approved antifungal drug (trade name Cresemba®) and its 
repurposing potential alone and in combination with available anti-HCMV drugs for the 
development of new anti-HCMV strategies.  
  
2. Materials and methods 
 
2.1 Compounds, cells, and viruses 
Isavuconazole (ICZ), ganciclovir (GCV), foscarnet, posaconazole (PCZ), and 
voriconazole (VCZ) were from Sigma-Aldrich. Letermovir was from Selleckchem.  
Human Foreskin Fibroblast (HFF) were from the American Type Culture Collection 
(ATCC) and were cultured in Dulbecco modified Eagle’s medium (DMEM) (Life 
Technologies) supplemented with 10% fetal bovine serum (FBS, Life Technologies), 100 
U/ml penicillin and 100 µg/ml streptomycin sulfate (P/S, both from Life Technologies).   
HCMV (strain AD169) was purchased from the ATCC. HCMV TB40E-UL32-EGFP 










(Sampaio et al., 2005) as well as HCMV VR1814 (kindly provided by G. Gerna, IRCCS 
Policlinico San Matteo, Pavia, Italy) recovered from a cervical swab from a pregnant woman 
(Revello et. al., 2001). HCMV 388438U clinical isolate was collected from a urine sample at 
the Microbiology and Virology Unity of Padua University Hospital (Italy) and was under 
passage 4 after primary isolation. HCMV strains resistant to antiviral drugs were obtained 
from the NIH AIDS Research and Reference Reagent Program (Rockville, MD) and 
previously described (Mercorelli et al., 2009).  
 
2.2 Plaque reduction assays 
Plaque reduction assays (PRAs) with HCMV were performed as previously described 
(Luganini et al., 2019). Briefly, HFF cells were seed d at a density of 1.5 × 105 cells per well 
in 24-well plates. The next day, the cells were infcted at 37°C with 80 Plaque Forming Unit 
(PFU) per well of the different viruses in serum-free DMEM. At 2 h p.i., the inocula were 
removed, cells were washed, and media containing various concentrations of each 
compound, 2% FBS, and 0.6% methylcellulose were added. After 10 days of incubation at 
37°C, cell monolayers were fixed and stained with crystal violet, and viral plaques were 
counted. 
 
2.3 Cell viability assays  
The effect on cell viability of test compounds was determined by the 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyl tetrazolium bromide (MTT; Sigma-Aldrich) method as described 











2.4 Virus yield reduction assays 
Virus yield reduction assays with HCMV were performed as previously described (Loregian 
et al., 2010). Briefly, HFF cells were plated at 2 × 104 cells per well in 96-well plates, 
incubated overnight, and infected the next day with HCMV AD169 at MOI of 0.05 PFU/cell. 
After virus adsorption for 2 h at 37°C, cells were washed and incubated with 0.2 ml of fresh 
medium containing 5% FBS in the absence or in the presence of test compounds. Plates were 
incubated for 5 days at 37°C and then subjected to one cycle of freezing and thawing. Virus 
titres were determined by transferring 0.1 ml aliquots from each well to a fresh 96-well 
monolayer culture of HFF cells, followed by 1:5 serial dilutions across the plate. Cultures 
were incubated for 7 days and at the end of incubation were fixed and stained, and the 
numbers of viral plaques were counted. 
 
2.5 Enzymatic assays in vitro 
Recombinant human CYP51 and its redox partner NADPH-cytochrome P450 reductase 
(CPR) were expressed in Escherichia coli and purified as described previously (Hargrove et 
al., 2016). The standard reaction mixture contained 0.5 µM hCYP51 and 1.0 µM CPR, 100 
µM L-α-1,2-dilauroyl-snglycerophosphocholine, 0.4 mg/ml isocitrate dehydrogenase, and 25 
mM sodium isocitrate in 50 mM potassium phosphate buffer (pH 7.2) containing 10% 
glycerol (v/v). After addition of the radiolabeled substrate ([3-3H] lanosterol, ~4,000 
dpm/nmol; dissolved in 45% aqueous 2-hydroxypropyl-β-cyclodextrin purchased from 
Sigma, w/v, final concentration 50 µM) and inhibitors (concentration range 0.1 - 250 µM), 
the mixture was preincubated for 30 s at 37 °C in ash king water bath. The reaction was 










ml of ethyl acetate. The extracted sterols were drid, dissolved in methanol, and analyzed by 
a reversed-phase HPLC system (Waters) equipped with a β-RAM detector (INUS Systems) 
using a NovaPak octadecylsilane (C18) column and a linear gradient 
water/acetonitrile/methanol (1.0:4.5:4.5, v/v/v) (solvent A) to CH3OH (solvent B), increasing 
from 0 to 100% B for 30 min at a flow rate of 1.0 ml/ in. The IC50 values were calculated 
using GraphPad Prism 6, with the percentage of lanoster l converted being plotted against 
inhibitor concentration and the curves fitted with non-linear regression (log(inhibitor) vs. 
normalized response - variable slope). 
 
2.7 Time-of-addition experiments 
For time-of-addition studies, HFF were seeded at a density of 104 cells per well in 96-well 
plates, incubated overnight, and infected the next day with HCMV AD169 at a MOI of 0.1. 
After virus adsorption for 2 h at 37°C, the viral inocula were removed, and the end of viral 
adsorption was considered the zero point of the timcourse. At 0, 3, 6, 9, 22, 26, 29, 33, 46, 
50, 53, 57, 70, 74, 77, and 80 h p.i., the cell medium was replaced with a medium containing 
20 μM ICZ or 10 μM GCV as a control. The plates were incubated at 37°C for a total of 100 
h p.i.; at this point, cells were subjected to one cycle of freezing and thawing, and the amount 
of viral progeny in each well of the microtiter plates was determined by titration on fresh 
HFF cultures.  
 
2.8 Drug combination studies 
To evaluate the combined effects of ICZ and different anti-HCMV drugs on HCMV AD169 










0.5-, 1-, 2-fold their respective EC50 for each combination of ICZ and anti-HCMV drugs at 
equipotent ratio. The 2-drug combination effects were assessed using the Chou-Talalay 
method (Chou, 2006) according to mass-action law based dynamic theory computed in the 
CalcuSyn software version 2.0 (Biosoft, Cambridge, UK).  
 
2.8 Statistical analysis 
All statistical analyses were performed using GraphPad Prism (San Diego, CA). 
 
 
3. Results  
 
3.1 Isavuconazole is an inhibitor of HCMV replication. 
In a drug repurposing campaign, we previously identifi d a series of molecules 
endowed with anti-HCMV activity (Mercorelli et al., 2016). Follow up studies revealed that 
some clinically approved imidazolic antifungal agents, i.e., miconazole, econazole, 
clotrimazole, ketoconazole, and a triazole, i.e., posaconazole, are broad-spectrum inhibitors 
of HCMV replication (Mercorelli et al., 2020). Here, we wished to investigate the possible 
anti-HCMV activity of a new, extended-spectrum antifungal, i.e., isavuconazole (ICZ).  
To this aim, plaque reduction assays (PRA) in HFF cells infected with HCMV were 
performed with ICZ and other anti-HCMV drugs as a control (Table 1). As reported in Fig. 
1A, ICZ showed a dose-dependent inhibitory effect on HCMV AD169 replication in HFF 
cells, similarly to what we previously reported forthe other antifungals endowed with anti-










In parallel, to exclude that the antiviral activity of ICZ might be due to cytotoxicity, 
its effect on the viability of uninfected HFF cells was evaluated by MTT assays. As reported 
in Fig. 1A, we did not observe cytotoxicity at the same concentration range at which the 
antiviral activity was evident. Thus, the antiviral effect was not due to inhibition of cell 
viability. Cytotoxicity assays were then performed with higher concentrations of ICZ (up to 
250 µM).  We noticed an evident tendency of the ICZto precipitate over time (at ≥125 µM at 
5 days post-treatment and at ≥62.5 µM at 10 days post-treatment), a phenomenon also 
described for the pharmaceutical formulation of Cresemba®. Therefore, the cytotoxic 
concentration that inhibited in vitro cell viability by 50% (CC50) at 5 days post-treatment 
resulted ~ 100 µM and a Selectivity Index (SI) of 14 was calculated (Table 1).  
To further confirm the anti-HCMV activity, the effects of ICZ on virus yield were 
analyzed in a multi-cycle viral growth experiment. As reported in Fig. 1B, treatment of 
infected cells with ICZ resulted in a dose-dependent inhibition of the virus progeny 
production, with an EC50 value of 3.16 µM (Table 1). 
 
3.2 Isavuconazole is a broad-spectrum inhibitor of HCMV, including drug-resistant viral 
strains. 
To investigate the spectrum of anti-HCMV activity of ICZ, we repeated the antiviral 
assays with a panel of HCMV strains, including low passage-number clinical isolates (TB40, 
VR1814, and 388438U, Fig. 1A). As reported in Table 2, the anti-HCMV activity of ICZ 
was not dependent on the viral strain, since the EC50 values obtained with different HCMV 










In addition, we tested ICZ against HCMV strains resistant to the available viral DNA 
polymerase inhibitors. Noteworthy, ICZ inhibited the replication of viruses resistant either to 
both GCV and cidofovir (GDGrP53) or to both foscarnet and acyclovir (PFArD100) at levels 
comparable to those observed for drug-sensitive strain  (Fig. 1C and Table 2). This result is 
of particular importance, since ICZ is clinically approved and the concentrations needed for 
antiviral activity fall within the therapeutic range as antifungal that is achieved in patients 
under therapy. Thus, ICZ may represent a potential therapeutic alternative in the case of 
infections with HCMV strains resistant or refractory to the available drugs.  
 
3.3 Isavuconazole inhibits human cytochrome P450 51 enzymatic activity in vitro. 
We previously linked the anti-HCMV activity of another azolic antifungal drug, PCZ, 
to its ability to inhibit the host enzyme human cytochrome P450 51 (hCYP51) (Mercorelli et 
al., 2020). In this context, we found that HCMV is able to induce the expression of hCYP51. 
Moreover, the pharmacological inhibition of hCYP51 resulted in an overall reduction of 
virus replication, production of infectious progeny, and infectivity of released viral particles 
(Mercorelli et al., 2020). We thus investigated theinhibitory activity of ICZ against purified 
hCYP51 in vitro, including PCZ and voriconazole (VCZ) as a positive and a negative 
control, respectively. As reported in Fig. 2, in enzymatic assays in vitro, both ICZ and PCZ 
inhibited the initial rate of lanosterol conversion catalyzed by purified hCYP51 in a dose-
dependent manner, with IC50 values of 50.5 and 8.3 µM, respectively. This inhibitory effect 
was not observed with VCZ (IC50 >250 µM). In these experiments, ICZ resulted about 6-fold 
less potent than PCZ in inhibiting hCYP51 enzyme in vitro, while a slightly lower anti-
HCMV activity in infected cells was observed for ICZ when compared with PCZ (EC50 










2 and Mercorelli et al., 2020), suggesting that ICZ might have other viral or cellular targets 
besides hCYP51.  
 
3.4 Isavuconazole affects HCMV viral progeny production at different times during the 
replication cycle 
To better characterize the mechanism of action of ICZ and to determine the phase of HCMV 
replication cycle that is affected by the drug we performed time-of-addition experiments, in 
which inhibitors are effective only if added prior to their target’s engagement in HCMV 
replication cycle. In these experiments, 20 μM ICZ, or 10 μM GCV for a comparison, was 
added to HCMV-infected HFF cells at different time points p.i. from 0 to 80 h p.i. According 
to the mechanism of action of GCV, i.e., inhibition f viral DNA synthesis, it markedly 
reduced virus yield when it was added up to 50-57 h p.i. (Fig. 3), consistent with the 
inhibition of the viral DNA polymerase.  
We previously reported that HCMV-induced overexpression of hCYP51, a host 
target of ICZ, was evident starting from 24-48 h p.i. (Mercorelli et al., 2020). Thus, we 
expected this to be also the time at which ICZ could start interfering with HCMV replication 
by inhibiting the host enzyme. In keeping with this, we measured an increase in HCMV titer 
when ICZ was added starting from 46 h p.i. (Fig. 3). Moreover, we noticed an additional 
reduction of the inhibitory effect of ICZ also when it was added within the first (0-22) h p.i. 
(Fig. 3). This result might support the hypothesis of the existence of other, early-acting 
target(s) of ICZ in HCMV infected cells.  
 










We finally explored the possibility that ICZ may act synergistically with available 
approved anti-HCMV drugs (ganciclovir, foscarnet, and letermovir) against virus replication, 
given that the mechanisms of action should be different. To test this hypothesis, PRAs were 
performed with equipotent combinations of ICZ combined with either GCV, FOS, or LMV, 
and the antiviral effects were determined by applying the Chou & Talalay method (Chou, 
2006). As reported in Table 3, a synergistic effect or ICZ and all the three drugs tested was 
observed, since the weighted Combination Index (CIwt) resulted <0.7 (Chou, 2006). When 
the single drug combinations were analyzed, the effct ranged from very strong synergism (at 
2 up to 0.25-fold the respective EC50) up to nearly additive effect for the combination of the 
ICZ with GCV or LMV at doses equal to 0.125-fold their respective EC50 (Tables S1-3), 
when the effect is probably lost by the fact that the drug concentrations are too low to act 
synergistically against the different targets.  We also observed that the combination of ICZ 
and LMV resulted less synergic than the combination of ICZ with DNA polymerase 
inhibitors, most likely because the timing of the respective targets’ engagement might be 
similar for ICZ and LMV and the synergistic inhibitory effect is less evident.  
The safety of the combinations at the highest dose (i.e., 4-, 2-, and 1-fold EC50) was 
assessed in uninfected HFF cells at 10 days p.i., the same time course of the plaque reduction 
experiments. We observed a slight inhibitory effect on cell viability after 10 days when the 
1- and 2-fold EC50 combinations of ICZ with the different drugs were tested, however not 
significant and very far from the CC50 (Fig. S1). Thus, the synergistic effect on the reduction 
of viral plaque numbers was most likely the result of combining two drugs with different 










observed a significant effect on the cell viability (Fig. S1). Therefore, this combination was 
excluded from the synergism studies.  
From this set of experiments, we also extrapolated th  Dose Reduction Index (DRI), 
which gives an estimation of the extent to which the dose of one analyzed drug may be 
reduced when used in combination with the second drug in the case of synergism, compared 
to the dose of the same drug used alone to achieve the same effect (Chou, 2006).  As an 
example, when GCV, FOS, or LMV are used in combinatio  with ICZ in vitro, 95% 
inhibition of HCMV replication may be obtained by reducing ICZ dose by 7-, 5-, and 3-fold, 
respectively, compared to ICZ used alone (Tables S4-6).  
 
4. Discussion  
In the present study, we have identified for the first time the anti-HCMV properties of 
ICZ, an antifungal drug which acts by inhibiting fungal CYP51 (14-α lanosterol 
demethylase), an essential enzyme and an important antimicrobial target. ICZ demonstrated 
broad anti-HCMV activity being able to inhibit the r plication of different HCMV strains, 
including clinical isolates and drug-resistant strains. We previously linked the anti-HCMV 
activity of another antifungal triazolic agent, posaconazole, to its ability to inhibit the human 
CYP51, which catalyzes a rate-limiting step in cholesterogenesis in mammals (Hargrove et 
al., 2016). ICZ also inhibited hCYP51 enzymatic activity in vitro, albeit less potently than 
PCZ. Thus, from this observation and taking into account the results of the time-of-addition 
experiments, we hypothesize that there might be additional target(s) of ICZ in HCMV-










In this context, the antiviral activity of ICZ against Lassa virus and other arenaviruses 
was recently reported (Zhang et al., 2020) and it has been observed that ICZ binds to the 
stable signal peptide-GP2 subunit interface of Lassa virus glycoprotein, thus inhibiting pH-
dependent viral entry. However, it seems unlikely that ICZ could act similarly against 
HCMV, a completely unrelated virus. Rather, since other azolic antifungal drugs show 
polypharmacology effects by interfering with different host pathways (Strating et al., 2015; 
Chen et al., 2016; Trinh et al., 2017; Meutiawati et al., 2018; Chen et al., 2016), we cannot 
exclude that ICZ might also interfere with known or yet-unidentified host pathways relevant 
for HCMV replication and thus contributing to its overall antiviral activity.  
PCZ, but to our knowledge not ICZ, is known to inhibit other host pathways 
including cholesterol intracellular trafficking (Trinh et al., 2017; Strating et al., 2015; 
Meutiawati et al., 2018) and Hedgehog signaling (Chen et al., 2016). Conversely, ICZ 
interactions with host proteins have not been equally well characterized yet. However, during 
preclinical and clinical development of ICZ, an off-target inhibitory effect of the drug on 
different human ion channels was observed, although it did not preclude its approval. In 
particular, voltage-dependent L-type calcium channels and potassium channels such as 
human ether-a-go-go (hERG) channel were the most sensitive to ICZ inhibition (unique 
among triazole antifungal agents) (Keirns et al., 2017 and https://www.accessdata.fda.gov). 
Intriguingly, different independent studies (including our drug repurposing studies) reported 
the early anti-HCMV activity of molecules that act by inhibiting these types of ion channel 
(Mercorelli et al., 2011; Mercorelli et al., 2016; Mercorelli et al.; 2018; Albrecht et al, 1987; 
Nokta et al., 1988; Fons et al., 1991). Thus, a hypothesis, that remains to be tested, could be 










contributes to virus replication and is sensitive to changes in ions homeostasis (particularly 
calcium). This hypothesis is in line with the inhibitory effects of the drug that we observed in 
the time-of-addition experiments. However, other vial or cellular targets cannot be 
excluded. Future studies will be aimed at identifying other possible targets of ICZ, if any.  
Isavuconazole is an azole antifungal agent active against a broad range of clinically 
relevant fungi and was approved in 2015 for the treatm nt of invasive aspergillosis and 
mucormycosis (McCormack, 2015). Its prodrug isavuconaz nium is rapidly converted by 
plasma esterases in the active form, isavuconazole. In healthy subjects, peak levels (Cmax) of 
ICZ range from 7.5 up to 20 mg/L (corresponding to 17.1 and 45.6 µM, respectively), 
depending on the daily dosage, which can range from200 to 600 mg (McCormack, 2015). 
Within SECURE clinical trial, Cmin was reported around 3.9 mg/L (corresponding to 8.9 µM)
(Maertens et al., 2016). In more recent studies, the Cthrough range of ICZ was reported 
between 1.33-4.22 mg/L (corresponding to 3-9.6 µM) in adult patients (Nannetti et al., 
2018), and between 2.15-8.54 mg/L (corresponding to 4.9-19.5 µM) in pediatric patients 
under clinical therapy (Decembrino et al., 2020). Thus, plasma levels of ICZ seem to be 
compatible with the dose required for the antiviral activity in vitro, since the EC50s that we 
found against HCMV (Table 1 and 2) fall in the clinical range reached in humans. 
Noteworthy, although in our study ICZ exhibited slightly higher EC50s than PCZ in antiviral 
cell-based assays, the clinically achievable levels of ICZ in vivo are much higher than those 
of PCZ. Indeed, peak levels for PCZ are reported around 1.5-2 µg/ml (2.2-2.9 µM) (Cornely 
et al., 2016 and 2017), concentrations which are below the EC50 against HCMV that was 
observed for PCZ (Mercorelli et al., 2020).  ICZ bioavailability can be influenced by 










possible that the concentration of the drug alone would result not sufficient to exert antiviral 
activity in vivo in some clinical settings. Importantly, our data suggest that much lower levels 
of ICZ could be required to inhibit HCMV when this drug is administered in combination 
with some approved anti-HCMV drugs. Thus, ICZ could be also exploited to potentiate the 
antiviral effect of GCV and FOS or LMV, although a drug-drug interaction with the latter 
cannot be excluded given that both drugs are CYP3A4 inhibitors. Clinical studies aimed at 
evaluating the efficacy of ICZ in controlling HCMV replication in vivo, both alone and in 
combination with anti-HCMV drugs used in clinical therapy, are needed to further validate 
the data we obtained in infected cells. 
 In conclusion, this study identified another FDA-approved drug already used in 
clinical practice in immunosuppressed patients who are at high risk of HCMV infections, 
endowed with potential of repurposing in the treatment of HCMV-associated infections. ICZ 
is well tolerated, and has a higher bioavailability than PCZ and a lower propensity to interact 
with other drugs compared to the other triazole antifungals (McCormack, 2015). Moreover, 
this study identified it as a broad-spectrum inhibitor of HCMV, including viral strains 
resistant to the currently available drugs. Thus, although a clinical validation of our 
observations is needed, ICZ may represent a valid altern tive in the case of infections 
sustained by resistant or refractory HCMV strains or in stem cell transplant recipients.  
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Fig. 1 Isavuconazole inhibits HCMV replication in a dose-dependent manner. (A) 
Plaque reduction assays were performed in HFF infected with the indicated HCMV strains 
and treated with different doses (from 0.1 to 25 µM) of ICZ. Cell viability curve in the 
presence of ICZ was obtained by MTT assays at 120 h. (B) Dose-dependent inhibition of 
virus progeny production by ICZ in HCMV-infected HFFs as determined by virus yield 
reduction assays. (C) Dose-dependent inhibition of the replication of HCMV strains resistant 
to currently available viral DNA polymerase inhibitors. In all panels, graphs report the mean 
± SD of n ≥ 3 independent experiments in duplicate. 
Fig. 2 Isavuconazole inhibits host hCYP51 enzymatic activity in vitro. Inhibition of 
enzymatic activity of purified hCYP51 by VCZ, ICZ, and PCZ (2-min reaction). Graph 
reports the mean ± SD of n = 3 independent experiments in duplicate.  
Fig. 3 Effects of addition of ICZ at different time-points after HCMV infection. HFF cells 
were infected with HCMV AD169 at an MOI of 0.1 and were then treated with ICZ or GCV 
at 0, 3, 6, 9, 22, 26, 29, 33, 46, 50, 53, 57, 70, 74, 77, and 80 h p.i. Virus titers derived from 
HCMV-infected cells treated with the drugs at each time point were determined by titration 
on fresh HFF monolayers. Graph reports the mean ± SD of n = 3 independent experiments in 
duplicate. 
 
Table 1  
Activity of ICZ and other anti-HCMV drugs against HCMV AD169. 
Compound EC50
a (µM), CIb EC50
c (µM), CI CC50
d (µM) SIe 
ICZ 7.38 (4.95-10.87) 3.16 (1.69-5.54) 100 ± 16 14 
GCV 1.56 (1.09-2.22) N.D. >250 >160 
FOS 28.4 (5.9-78.3) N.D. N.D. N.D. 










a 50% Effective Concentration, the compound concentration that inhibits 50% of plaque formation, as 
determined by PRAs against HCMV AD169 in HFF cells. Reported values represent data derived from n = 3 
independent experiments in duplicate. 
b CI, Confidence Interval (95% Profile likelihood, cal ulated with GraphPad Prism 8.0 software). 
c 50% Effective Concentration, the compound concentration that inhibits 50% of virus yield in HFF cells. 
Reported values represent data derived from n = 3 independent experiments in duplicate. 
N.D., Not Determined. 
 
Table 2 
Activity of ICZ against different HCMV strains. 
HCMV Strain  Drug resistance ICZ EC50
a (µM), CIb Controlc EC50 (µM), CI 
TB40 None 4.44 (2.47-7.63) N.D. 
VR1814 None 5.13 (2.48-9.89) N.D. 
388438U None 3.88 (1.49-8.96) N.D. 
PFArD100 FOS, ACV 5.21 (2.38-10.84) 278 (241-312) 
GDGrP53 GCV, CDV 6.17 (3.14-11.56) 74.4 (42.4-145.5) 
a 50% Effective Concentration, the compound concentration that inhibits 50% of plaque formation, as 
determined by PRAs in HFF cells. Reported values represent data derived from n ≥ 3 independent experiments 
in duplicate.  
b CI, Confidence Interval (95% Profile likelihood, cal ulated with Graphpad Prism 8.0 software). 
c GCV was used for GDGrP53 and FOS for PFArD100.  
N.D., Not Determined.  
 
Table 3 




CI values extrapolated at the indicated % of virus 





 50 75 90 95   
ICZ + GCV (3.5:1) 0.635±0.018 0.386±0.039 0.243±0.042 0.180±0.039 0.258 Strong 
Synergism 
ICZ + FOS (1:4) 0.593±0.021 0.422±0.029 0.306±0.012 0.284±0.035 0.335 Synergism 
ICZ + LMV 
(3,500:1) 
0.750±0.031 0.624±0.022 0.522±0.037 0.464±0.019 0.542 Synergism 
 
a EC50 values for HCMV strain AD169 considered for each drug (approximating values obtained in PRA and 
reported in Table 1). 
b EC50 of drug1/EC50 of drug2 yielding an equipotent concentration ratio between the two combined drugs. 
c Combination index (CI) at the indicated % of virus inhibition values extrapolated by analysis with CalcuSyn 
Software. CI values represent the mean ± SD of n = 3 independent experiments in triplicate or duplicate. 
d Weighted average CI. Values were calculated as CIwt = (CI50 + 2 x CI75 + 3 x CI90 + 4 x CI95)/10. 
e Drug combination effect defined as: strong synergism for 0.1<CIwt<0.3 and synergism for 0.3<CIwt<0.7, 
































1. Isavuconazole (ICZ) is a clinically approved antifungal that inhibits human cytomegalovirus 
(HCMV) replication. 
2. ICZ is a broad-spectrum HCMV inhibitor, including clinical isolates and drug-resistant 
strains within its clinical range. 
3. ICZ inhibits in vitro the activity of human CYP51 enzyme, required for productive HCMV 
infection. 
4. ICZ acts synergistically with ganciclovir, foscarnet, and letermovir, indicating a repurposing 
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